SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Polyrizon Completes Enrollment of 120 Patients in U.S. Allergy-Blocker Study

Polyrizon said enrollment is complete for all 120 patients in its U.S. clinical study of Nasarix allergy blocker.

PLRZ

Related stories